Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma
Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma who are ineligible to undergo a transplant.
Flow Cytometry, Cytomorphological Features Correlate With MDS Prognosis
Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome.
Cabozantinib Plus Atezolizumab Significantly Improves PFS in Metastatic CRPC
Combination treatment with cabozantinib and atezolizumab did not produce any new safety signals in the treatment of those with metastatic castration-resistant prostate cancer in the phase 3 CONTACT-02 trial.
Adaptive SBRT May Reduce GU/GI Toxicity Risk in Prostate Cancer
A meta-analysis found that the use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) correlated with fewer acute grade 2 or higher gastrointestinal (GI) or genitourinary (GU) toxicities compared with CT-guided non-adaptive SBRT in patients with prostate cancer.
FDA Approves FoundationOne CDx as Companion Diagnostic for Niraparib/Abiraterone in mCRPC
The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) harboring a BRCA mutation.
Investigators Discontinue Trial Assessing Magrolimab Combo in Higher-Risk MDS
Investigators will submit data from the phase 3 ENHANCE trial evaluating magrolimab plus azacitidine in higher-risk myelodysplastic syndromes for presentation at a future medical meeting.
FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer
Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.
2 Clarke Drive Cranbury, NJ 08512